Epigenomics Moves Methylation-Based Prostate Cancer Prognostic to Affy Platform

Dec 13, 2006

NEW YORK (GenomeWeb News) — Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.

The company said a concordance study showed a 98-percent agreement between the two platforms.

Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Featured White Papers

FFPE controls for use with Ion AmpliSeq and Oncomine ALK, RET, and ROS1 fusion assays

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu